Physician profile
Nirupama Vallala
NPI 1598938540
$1,222.34
in general payments reported to CMS, 2019-2025
20 companies · $546 in 2025
The $546 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $34.21 · 2023: $191 · 2024: $243 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $208.76 | 2021 | |
| Pfizer INC. | $112.14 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $108.73 | 2022-2025 | Lifevest |
| Amgen INC. | $108.18 | 2023-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $103.27 | 2023-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $96.66 | 2023-2025 | |
| Intuitive Surgical, INC. | $74.75 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $63.50 | 2024-2025 | Wainua, Farxiga |
| Esperion Therapeutics, INC. | $58.23 | 2024-2025 | Nexletol |
| Lantheus Medical Imaging, INC. | $44.60 | 2025 | |
| Heartflow, INC. | $43.07 | 2025 | |
| Scpharmaceuticals INC. | $35.39 | 2024 | |
| Boston Scientific Corporation | $32.25 | 2025 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $27.74 | 2023 | Xarelto |
| Merck Sharp & Dohme LLC | $19.81 | 2023 | Verquvo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $18.97 | 2025 | Assure Wcd |
| Cvrx, INC. | $18.68 | 2025 | Barostim Neo System |
| Bridgebio Pharma, INC. | $17.57 | 2025 | Attruby |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.49 | 2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $14.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirupama Vallala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.